Last €25.79 EUR
Change Today -0.71 / -2.68%
Volume 4.0
GOV On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 3:16 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

insulet corp (GOV) Snapshot

Open
€26.17
Previous Close
€26.50
Day High
€26.70
Day Low
€25.76
52 Week High
12/8/14 - €38.80
52 Week Low
05/9/14 - €22.53
Market Cap
1.4B
Average Volume 10 Days
3.2
EPS TTM
--
Shares Outstanding
56.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INSULET CORP (GOV)

insulet corp (GOV) Related Bloomberg News

View More Bloomberg News

insulet corp (GOV) Related Businessweek News

No Related Businessweek News Found

insulet corp (GOV) Details

Insulet Corporation develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. The company offers OmniPod Insulin Management System (OmniPod System), which consists of the OmniPod, a disposable insulin infusion device that integrates an infusion set, automated cannula insertion, insulin reservoir, drive mechanism, and batteries; and a handheld, wireless personal diabetes manager. It is also involved in the distribution of durable medical equipment, including blood glucose testing supplies, insulin pumps, pump supplies, pharmaceuticals, and other products for the management and treatment of diabetes. The company sells its OmniPod System directly to patients through referrals from healthcare professionals and through patient leads, as well as through third-party distributors. Insulet Corporation was founded in 2000 and is based in Bedford, Massachusetts.

478 Employees
Last Reported Date: 02/28/14
Founded in 2000

insulet corp (GOV) Top Compensated Officers

Director of Advanced Technology and Director
Total Annual Compensation: $376.9K
General Counsel and Secretary
Total Annual Compensation: $265.0K
Executive Officer
Total Annual Compensation: $306.3K
Compensation as of Fiscal Year 2013.

insulet corp (GOV) Key Developments

Insulet Corporation Provides Revenue Guidance for the Fourth and Full Year Ended December 31, 2014; Provides Revenue Guidance for the Year 2015

Insulet Corporation provided revenue guidance for the fourth and full year ended December 31, 2014. For the quarter, the company expects revenue will be in the range of $71 to $73 million, versus prior estimates of $76 to $81 million a year ago. The company expects growth in the fourth quarter of 2014 of approximately 10% from its U.S. direct diabetes business and approximately 40% from its international diabetes business compared to the same period last year. For the year, the company expects revenues to be in the range of $287 to $289 million, versus prior estimates of $292 to $297 million. For the year 2015, the company expects that revenues associated with non-insulin drug delivery products will be in the range of $10 to $20 million.

Insulet Corporation Announces Management Changes

Insulet Corporation announced a number of management team changes, including the appointment of six distinguished executives to commercial and corporate positions. boldCommercial Operations Leadership Changes: Philip Hildale has been named Vice President, Sales and is responsible for overseeing the Company's U.S. diabetes sales operations. Mr. Hildale has a distinguished background in sales leadership, most recently as Vice President of Sales at Liposcience Inc. Prior to this role, he served in various sales and sales leadership roles at Hologic Inc., Cytyc Corporation and Ortho-McNeil Pharmaceutical; Christopher Gilbert has joined as Vice President, Marketing and is responsible for the Company's diabetes-related marketing efforts. Prior to this position, Mr. Gilbert held numerous marketing roles at Hologic, most recently leading the marketing efforts within Hologic's Gynecological Surgical Division. He also held a number of financial roles including business analyst at Staples Inc. and division controller at Merkert Enterprises; Daniel Trodden has assumed the role of Vice President, Managed Care. Mr. Trodden is a proven leader, working with managed care organizations ranging from private payors to government and strategic markets. He most recently served in several managed care roles at Genomic Health Inc., where he was responsible for leading the efforts to secure coverage and negotiate in-network status and payor value-based reimbursement rates. He previously served in various sales and managed care roles at Cytyc, Tap Pharmaceuticals Inc. and U.S. Healthcare. boldCorporate Leadership Changes: Annette Brewster has joined as Vice President, Customer Care, reporting to Patrick Ryan, Chief Operating Officer, and is responsible for the Company's customer service operations including inside sales, reimbursement and customer support. Ms. Brewster most recently served as Director of Enterprise Account Management at athenahealth Inc. and in numerous sales, marketing and services management roles at Hologic and Cytyc; Glenn Weatherley has been appointed Vice President, International, reporting to Patrick Sullivan, President and Chief Executive Officer. He is responsible for the Company's international diabetes operations, primarily focused in Europe. Mr. Weatherly, who is based in the United Kingdom, brings more than 30 years of international sales and marketing experience and most recently served as Vice President of European Sales within the Diagnostics Division at Hologic. Mr. Weatherley has held various other sales and management roles at Hologic and Cytyc; Deborah Gordon has been named Vice President, Investor Relations and Corporate Communications, reporting to Patrick Sullivan. Ms. Gordon will assume the role on February 2 and will be responsible for the Company's communications with Wall Street, public relations activities and employee communications. Ms. Gordon has a unique skillset that combines strong Wall Street and accounting/finance experience. She most recently served as Vice President, Investor Relations and Corporate Communications at Hologic and prior to this, held a number of financial leadership roles within Hologic and Cytyc Corporation. She also held roles of increasing responsibility in the audit practice at Deloitte & Touche. boldLeadership Transition: Peter Devlin has resigned as the Company's Chief Commercial Officer effective January 6, 2015. Mr. Devlin has served in the position since August 2009 and will remain an employee of the Company through April 3, 2015 to assist with a smooth transition. A search for Mr. Devlin's successor is currently underway, and the commercial organization will report directly to Mr. Sullivan in the interim.

Insulet Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 01:30 PM

Insulet Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 01:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Patrick J. Sullivan, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GOV:GR €25.79 EUR -0.71

GOV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $138.08 USD -2.23
DexCom Inc $59.78 USD -1.22
Smiths Group PLC 1,127 GBp +17.00
Takeda Pharmaceutical Co Ltd ¥5,903 JPY +43.00
Tandem Diabetes Care Inc $12.29 USD -0.19
View Industry Companies
 

Industry Analysis

GOV

Industry Average

Valuation GOV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.8x
Price/Book 20.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSULET CORP, please visit www.insulet.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.